[
    [
        {
            "time": "2019-08-29",
            "original_text": "Big Pharma kills signature drug at center of $5.8 billion South S.F. deal",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "signature drug",
                    "$5.8 billion",
                    "South S.F. deal"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Big Pharma kills signature drug at center of $5.8 billion South S.F. deal",
                "Correlation": 7,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-29",
            "original_text": "Health Care Sector Update for 08/29/2019: AZN, ABBV, IBIO",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "AZN",
                    "ABBV",
                    "IBIO"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 08/29/2019: AZN, ABBV, IBIO",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-08-29",
            "original_text": "UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T",
            "features": {
                "keywords": [
                    "AbbVie",
                    "abandons",
                    "late-stage",
                    "lung cancer",
                    "Rova-T"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-29",
            "original_text": "AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Discontinues",
                    "Phase III",
                    "Trial",
                    "Small-Cell Lung Cancer"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-29",
            "original_text": "AbbVie is shutting down its troubled Rova-T R&D program",
            "features": {
                "keywords": [
                    "AbbVie",
                    "shutting down",
                    "Rova-T",
                    "R&D program"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie is shutting down its troubled Rova-T R&D program",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-29",
            "original_text": "AbbVie terminates late-stage lung cancer trial",
            "features": {
                "keywords": [
                    "AbbVie",
                    "terminates",
                    "late-stage",
                    "lung cancer",
                    "trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie terminates late-stage lung cancer trial",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-29",
            "original_text": "AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Discontinues",
                    "Rovalpituzumab Tesirine",
                    "Rova-T",
                    "Research and Development Program"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]